Overview

Sentinel Node Localization and Staging With Low Dose Superparamagnetic Iron Oxide

Status:
Active, not recruiting
Trial end date:
2023-04-30
Target enrollment:
Participant gender:
Summary
Sentinel lymph node (SLN) status is pivotal for treatment decisions in breast cancer patients. The dual technique with Technetium99m (Tc99) and blue dye (BD) is yet the current routine for SLN detection. However, the same reliability has been presented by superparamagnetic iron oxide nanoparticles (SPIO). The aim of this study was to determine if SLN detection using ultra-low dose SPIO is feasible.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Sahlgrenska University Hospital, Sweden